Ergoloid Mesylates
- Atc Codes:C04AE01
- CAS Codes:8067-24-1#11032-41-0
- PHARMGKB ID:8067-24-1#11032-41-0
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Ergomed, Hydergin; Belgium: Hydergine, Ibexone, Stofilan; Finland: Hydergin; Germany: DCCK Tropflösung; Greece: Huperlodid, Hydergine, Normanomin; Italy: Hydergina; Poland: Dihydroergotoxinum; Portugal: Hydergine; Slovenia: Redergin; Spain: Hydergina.
North America
Canada: Hydergine; USA: Ergoloid Mesylates, Hydergine.
Latin America
Argentina: Ergoxina, Hydergina, Vimotadine; Mexico: Hydergina.
Asia
Japan: Coax, Cortagon, Elmesatt, Epos, Hydergine, Inorter, Vasolax, Youginin.
Drug combinations
Ergoloid Mesylates and Cinnarizine
Ergoloid Mesylates and Citicoline
Ergoloid Mesylates, Clopamide, and Reserpine
Chemistry
Ergoloid Mesylates: Dihydroergocornine mesylate: C~31~H~41~N~5~O~5~ CH~4~O~3~S. Mw: 659.79; Dihydroergocristine mesylate: C~35~H~41~N~5~O~5~ CH~4~O~3~S. Mw: 707.84; Dihydro-α-ergocryptine mesylate: C~32~H~43~N~5~O~5~ CH~4~O~3~S. Mw: 673.82; Dihydro-β-ergocryptine mesylate: C~32~H~43~N~5~O~5~ CH~4~O~3~S. Mw: 673.82. (1) Ergotaman-3′,6′,18-trione, 9,10-dihydro-12′-hydroxy-2′,5′-bis(1-methylethyl)-, (5’α,10α)-, monomethanesulfonate (salt) mixture with 9,10α-dihydro-12′-hydroxy-2′-(1-methylethyl)-5’α-(phenylmethyl)ergotaman-3′,6′,18-trione monomethanesulfonate (salt), 9,10α-dihydro-12′-hydroxy-2′-(1-methylethyl)-5’α-(2-methylpropyl)ergotaman-3′,6′,18-trione monomethanesulfonate (salt), and 9,10α-dihydro-12′-hydroxy-2′-(1-methylethyl)-5’α-(1-methylpropyl)ergotaman-3′,6′,18-trione monomethanesulfonate (salt); (2) Dihydroergotoxine monomethanesulfonate; (3) An equiproportional mixture of dihydroergocornine mesylate, dihydroergocristine mesylate, and ratio of dihydro-α-ergocryptine mesylate to dihydro-β-ergocryptine mesylate is 1.5-2.5:1. CAS-8067-24-1; CAS-11032-41-0 (dihydroergotoxine)(1980).
Pharmacologic Category
Sympatholytic (Adrenergic Blocking) Agents; Non-selective α-Adrenergic Blocking Agents. Ergot Derivative. Anti-Dementia Agents. (ATC-Code: C04AE01).
Mechanism of action
An equiproportional mixture of the mesylate salts of the hydrogenated derivatives of 3 naturally-occurring ergot alkaloids. Ergoloid mesylates do not have the vasoconstrictor effects of the natural ergot alkaloids. Exact mechanism in dementia is unknown.
Therapeutic use
Treatment of cerebrovascular insufficiency in primary progressive dementia, Alzheimer’s dementia, and senile onset.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to ergot or any component of the formulation. Acute or chronic psychosis. Contraindicated with potent inhibitors of CYP3A4 (protease inhibitors, azole antifungals, and some macrolide antibiotics).
Warnings and precautions
Ergot alkaloids associated with fibrotic valve thickening (e.g. aortic, mitral, tricuspid); usually associated with long-term, chronic use. Rare cases of pleural and/or retroperitoneal fibrosis reported with prolonged daily use. Concomitant use with potent inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics) and ergot alkaloids associated with acute ergot toxicity (ergotism); certain ergot alkaloids (e.g. ergotamine and dihydroergotamine) are contraindicated by the manufacturer. Use with caution in the elderly.